title: Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
abstract: Conflicting results about the prognostic value of Glasgow Prognostic Score (GPS) in hepatocellular carcinoma (HCC) patients have been reported. We searched the available articles and performed the meta-analysis to clarify the predictive value of GPS in HCC patients' outcome.A systematic literature search was conducted using PubMed (Medline), Embase, Cochrane Library, Web of Science, ChinaInfo, and Chinese National Knowledge Infrastructure for all years up to September 2015. Studies analyzing the relationship of GPS and survival outcome were identified. Hazard ratio (HR) with 95% confidence interval (CI) was calculated to assess the risk.A total of 10 studies were finally enrolled in the meta-analysis. The pooled estimates demonstrated a significant relationship between elevated GPS and inferior overall survival in patients with HCC (HR = 2.156, 95% CI: 1.696-2.740, P < 0.001). Patients with increased GPS had a tendency toward shorter progression-free survival (HR = 1.755, 95% CI: 0.943-3.265, P = 0.076). And elevated GPS was found to be significantly associated with advanced Child-Pugh class (odds ratio = 25.979, 95% CI: 6.159-109.573, P < 0.001). The publication bias analysis revealed that there was publication bias in the meta-analysis.Glasgow Prognostic Score may be an independent prognostic factor in patients with HCC. More well-designed studies with adequate follow-up duration are warranted.
authors.affiliation: From the Department of Abdominal Surgical Oncology (M-XL, X-YB, Z-YL, ZH, J-GZ, J-JZ, Y-FZ, HZ, J-QC) and Department of Radiofrequency Ablation (YH), Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC), Cancer Hospital, Beijing, People's Republic of China.
authors.forename: Mu-Xing
authors.initials: MX
authors.lastname: Li
authors.forename: Xin-Yu
authors.initials: XY
authors.lastname: Bi
authors.forename: Zhi-Yu
authors.initials: ZY
authors.lastname: Li
authors.forename: Zhen
authors.initials: Z
authors.lastname: Huang
authors.forename: Yue
authors.initials: Y
authors.lastname: Han
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Zhou
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Zhao
authors.forename: Ye-Fan
authors.initials: YF
authors.lastname: Zhang
authors.forename: Hong
authors.initials: H
authors.lastname: Zhao
authors.forename: Jian-Qiang
authors.initials: JQ
authors.lastname: Cai
mesh_terms: D002097:C-Reactive Protein / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000175:diagnosis* / Q000401:mortality*; D006305:Health Status Indicators; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality*; D011379:Prognosis; D012709:Serum Albumin / Q000032:analysis; D016019:Survival Analysis
chemical_list: D012709:Serum Albumin; D002097:C-Reactive Protein